CCR1 chemokine receptor antagonist

被引:43
作者
Saeki, T [1 ]
Naya, A [1 ]
机构
[1] Banyu Pharmaceut Co Ltd, Merck Res Labs, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan
关键词
chemokine; chemokine receptor; CCR1; antagonist;
D O I
10.2174/1381612033454937
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The selective accumulation and activation of leukocytes in inflamed tissues contributes to the pathogenesis of inflammatory and autoimmune diseases such as infection, rheumatoid arthritis, allergic asthma, atopic dermatitis, and multiple sclerosis. A substantial body of reports suggests that chemokines and their receptors, which belong to a family of seven transmembrane G-protein coupled receptors (GPCR), may be involved in the selective accumulation and activation of leukocytes in inflamed tissues, and in the pathogenesis of inflammatory and autoimmune diseases. One such receptor is CCR1 which is a receptor for CC chemokines, such as CCL5 (RANTES) and CCL3 (MIP-1alpha). The involvement of CCR1 in immunological diseases now is documented in several preclinical studies with CCR1 deficient mice, anti-CCR1 antibodies and CCR1 antagonists, suggesting that CCR1 may be an attractive therapeutic target for a variety of diseases. Publications and patents describing CCR1 antagonists and their pharmacological effects have recently been disclosed. This review highlights the biology and pathophysiology of CCR1, and some of its currently reported antagonists. Additionally, our approach to CCR1 drug discovery is summarized.
引用
收藏
页码:1201 / 1208
页数:8
相关论文
共 76 条
[1]   Increased MCP-1, RANTES, and MIP-1 alpha in bronchoalveolar lavage fluid of allergic asthmatic patients [J].
Alam, R ;
York, J ;
Boyars, M ;
Stafford, S ;
Grant, JA ;
Lee, J ;
Forsythe, P ;
Sim, T ;
Ida, N .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (04) :1398-1404
[2]   Cytokine and chemokine based control of HIV infection and replication [J].
Alfano, M ;
Poli, G .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (11) :993-1013
[3]   A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation [J].
Anders, HJ ;
Vielhauer, V ;
Frink, M ;
Linde, Y ;
Cohen, CD ;
Blattner, SM ;
Kretzler, M ;
Strutz, F ;
Mack, M ;
Gröne, HJ ;
Onuffer, J ;
Horuk, R ;
Nelson, PJ ;
Schlöndorff, D .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (02) :251-259
[4]   Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model [J].
Barnes, DA ;
Tse, J ;
Kaufhold, M ;
Owen, M ;
Hesselgesser, J ;
Strieter, R ;
Horuk, R ;
Perez, HD .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (12) :2910-2919
[5]   Airway remodeling is absent in CCR1-/- mice during chronic fungal allergic airway disease [J].
Blease, K ;
Mehrad, B ;
Standiford, TJ ;
Lukacs, NW ;
Kunkel, SL ;
Chensue, SW ;
Lu, B ;
Gerard, CJ ;
Hogaboam, CM .
JOURNAL OF IMMUNOLOGY, 2000, 165 (03) :1564-1572
[6]   Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS) [J].
Bone, RC .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (08) :680-687
[7]  
Bonecchi R, 1999, J IMMUNOL, V162, P474
[8]   Identification of a non peptidic RANTES antagonist [J].
Bright, C ;
Brown, TJ ;
Cox, P ;
Halley, F ;
Lockey, P ;
McLay, IM ;
Moore, U ;
Porter, B ;
Williams, RJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (07) :771-774
[9]  
BROWN MF, Patent No. 0157023
[10]  
BROXMEYER HE, 1990, BLOOD, V76, P1110